ストックスクリーナーアプリを入手
14.19
2.81%
-0.41
アフターアワーズ：
14.18
-0.010
-0.07%
前日終値:
$14.60
開ける：
$14.51
24時間の取引高:
167.78K
Relative Volume:
0.80
時価総額：
$242.73M
収益：
$10.73M
当期純損益:
$-455.74M
株価収益率:
-3.7511
EPS:
-3.7829
ネットキャッシュフロー:
$-502.70M
1週間 パフォーマンス:
+4.03%
1か月 パフォーマンス:
+22.96%
6か月 パフォーマンス:
-14.21%
1年 パフォーマンス:
-70.72%
1日の値動き範囲:
$14.01
$14.65
1週間の範囲:
$13.10
$14.68
52週間の値動き範囲:
$11.13
$73.06
Atrium Therapeutics Inc Stock (RNA) Company Profile
名前
Atrium Therapeutics Inc
セクター
電話
858-401-7900
住所
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
14.19 | 230.58M | 10.73M | -455.74M | -502.70M | -3.7829 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | 開始されました | Wells Fargo | Overweight |
| 2025-09-17 | 開始されました | Roth Capital | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Bernstein | Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-06-11 | 開始されました | Raymond James | Strong Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-09-24 | 開始されました | Goldman | Buy |
| 2024-08-28 | 開始されました | Barclays | Overweight |
| 2024-05-03 | 開始されました | BofA Securities | Buy |
| 2024-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-05-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-31 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Strong Buy |
| 2021-09-07 | 開始されました | Evercore ISI | Outperform |
| 2021-06-17 | 開始されました | Needham | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | Cowen | Outperform |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | SVB Leerink | Outperform |
| 2020-07-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Atrium Therapeutics Inc (RNA) 最新ニュース
BRIEF-Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - Dailyhunt
A new Atrium hire gets options on 11,000 shares and 5,500 restricted units - Stock Titan
Atrium (RNA) Momentum: Records a 1.68% Decrease to $13.48; Technical View: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingBreakaway Gap - vinanet.vn
Atrium (RNA) Closing Snapshot: Closes 0.93% Lower at $12.84 in Latest Trading; Level Check: the Supplied Trading Band Runs From $12.20 to $13.48 in the Latest ReadingStop Loss Guidance - Vinanet
Atrium Therapeutics (RNA) Inches Higher: 0.93% Gain Reinforces Support ZoneDark Pool Sentiment - vinanet.vn
Atrium Therapeutics (RNA) Climbs 2.4% as Shares Hold Above Critical SupportCup and Handle - dars.gov.et
Atrium Therapeutics, Inc. (RNA) Stock Analysis: 94.70% Potential Upside Catches Investor Attention - DirectorsTalk Interviews
Atrium Therapeutics (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentDividend Earnings Report - vinanet.vn
Atrium Therapeutics (RNA) Jumps 4.14% to $12.84 as Buyers Defend Key SupportValue Area High - vinanet.vn
Atrium Therapeutics (RNA) Climbs 4.1% to $12.84 as Biotech Sentiment StrengthensLow Beta Factor - Vinanet
Atrium Therapeutics (RNA): RA Capital and affiliates report 0% beneficial ownership - Stock Titan
Aterian: Q2 Earnings Snapshot - AOL.com
Sessa Capital discloses 8.8% Atrium Therapeutics (RNA) ownership through managed funds - Stock Titan
T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A - Stock Titan
Atrium Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | RNA | US04965N1046 - marketscreener.com
Atrium Therapeutics Q2 Net Loss Widens to $21.6 Million on Higher Spending - Minichart
Atrium Therapeutics Earns $15M BMS Milestone Payment, Advances Gene Therapy Candidate - Minichart
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Heart drug developer Atrium Therapeutics' Q2 loss widens as expenses rise - TradingView
Atrium Therapeutics Q2 Results: Sales beat 50%, EPS miss widens - scanx.trade
Atrium Therapeutics, Inc. Q2 2026: Revenue $3M, EPS $(1.18) — 10-Q Summary - TradingView
Atrium Therapeutics (RNA) grows collaboration revenue to $22.6M while scaling R&D spend - Stock Titan
Atrium Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
META_TITLE_QUOTE - Yahoo Finance
Atrium Therapeutics Reports Second Quarter 2026 Financial Results - KITV
Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B - Fierce Biotech
Atrium Therapeutics Earns $15M BMS Milestone - Contract Pharma
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb By Investing.com - Investing.com Nigeria
Atrium Therapeutics Earns Another $15 Million Milestone Payment From Bristol Myers Squibb - marketscreener.com
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb - Investing.com
Fate Therapeutics: Q2 Earnings Snapshot - AOL.com
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire
Atrium Therapeutics (RNA) Sheds 0.8% to $12.17 as $11.56 Support LoomsSpring Pattern - dars.gov.et
Atrium Therapeutics (RNA) Holds Steady at $12.23 as Shares Trade Within Established RangeInsider Selling Alerts - vinanet.vn
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a Potential 102.59% Upside in the Booming RNA Therapeutics Market - DirectorsTalk Interviews
H.C. Wainwright Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Actinium: Q2 Earnings Snapshot - AOL.com
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Atrium Therapeutics (RNA) Climbs 1.99% to $11.77, Approaching Key Resistance at $12.36Volume Oscillator - dars.gov.et
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A 120% Upside Potential Awaits Investors - DirectorsTalk Interviews
RNA Q1 2026 Earnings: Narrower-Than-Expected Loss Drives 2.5% Share UpswingReturn On Capital - Vinanet
RNA Q1 2026 Earnings: Narrower-than-expected loss fails to lift sharesForward Guidance Trends - vinanet.vn
BlackRock (RNA holder) discloses 6.6% Atrium Therapeutics stake in amended ownership filing - Stock Titan
Atrium Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNA - tradingview.com
Atrium Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockPre-Announcement Alert - Vinanet
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Atrium Therapeutics (RNA): Flat Trading as Stock Hovers Near Key Support LevelsMonthly Profile - dars.gov.et
Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA) - The Globe and Mail
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Commercial Spend Weighs on ResultsEBITDA Analysis - dars.gov.et
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Provides a Modest SurpriseLow Estimate Range - dars.gov.et
Wells Fargo Maintains Atrium Therapeutics(RNA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Atrium Therapeutics Inc (RNA) 財務データ
収益
当期純利益
現金流量
EPS
Atrium Therapeutics Inc (RNA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):